Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-11-29
2009-10-27
Tsang, Cecilia (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S008100, C514S017400, C530S322000, C530S330000
Reexamination Certificate
active
07608591
ABSTRACT:
The present invention relates to new agents and methods useful for preventing, treating and diagnosing diseases such as cancer. For example, the invention relates to prodrug agents useful for targeting and delivering cytotoxic drugs to cancerous cells.
REFERENCES:
patent: 4036945 (1977-07-01), Haber
patent: 4317815 (1982-03-01), Coy et al.
patent: 4331647 (1982-05-01), Goldenberg
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4507232 (1985-03-01), Tamai et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4938949 (1990-07-01), Borch et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4980464 (1990-12-01), Naito et al.
patent: 5021236 (1991-06-01), Gries et al.
patent: 6004933 (1999-12-01), Spruce et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6245750 (2001-06-01), Shepard
patent: 6506559 (2003-01-01), Greenwald et al.
patent: 6545131 (2003-04-01), Isaacs et al.
patent: 6624142 (2003-09-01), Fire et al.
patent: 6625142 (2003-09-01), Joffe et al.
patent: 6683061 (2004-01-01), Shepard et al.
patent: 6720306 (2004-04-01), Greenwald et al.
patent: 2002/0147138 (2002-10-01), Firestone et al.
patent: 2003/0054387 (2003-03-01), Chen et al.
patent: 2003/0216298 (2003-11-01), Gengrinovitch
patent: 2006/0251663 (2006-11-01), Mariscal-Gonzalez et al.
patent: 0045665 (1982-02-01), None
patent: 0404097 (1990-12-01), None
patent: WO-93/11161 (1993-06-01), None
patent: WO-98/13059 (1998-04-01), None
patent: WO-00/64945 (2000-11-01), None
patent: WO-01/07454 (2001-02-01), None
patent: WO-01/62300 (2001-08-01), None
patent: WO-01/85960 (2001-11-01), None
patent: WO-02/20715 (2002-03-01), None
patent: WO-02/096910 (2002-12-01), None
patent: WO-03/016335 (2003-02-01), None
patent: WO03098991 (2003-12-01), None
patent: WO-2004/111192 (2004-12-01), None
Hong et al. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid. Cancer Research. Jul. 15, 1990. 50. 4401-4406.
Merrifield. Concept and Early Development of Solid-Phase Peptide Synthesis. Methods in Enzymology. 1997. vol. 289. pp. 3-13.
Albini, A., “A Rapid in Vitro Assay for Quantitating the Invasive Potential of Tumor Cells”,Cancer Research, 47(2), (Jun. 15, 1987), 3239-3245.
Almquist, R. G., et al., “Synthesis and Biological Activity of a Ketomethylene Analogue of a Tripeptide Inhibitor of Angiotensin Converting Enzyme”,Journal of Medicinal Chemistry, 23, (1980), 1392-1398.
Alvarez-Fernandez, M., et al., “Inhibition of Mammalian Legumain by Some Cystatins Is Due to a Novel Second Reactive Site”,The Journal of Biological Chemistry, 274(27), (1999), 19195-19203.
Asgian, J. L., et al., “Aza-Peptide Epoxides: A New Class of Inhibitors Selective for Clan CD Cysteine Proteases”,Journal of Medicinal Chemistry, 45(23), (2002), 4958-4960.
Barrett, A. J., et al., “Evolutionary Lines of Cysteine Peptidases”,Biological Chemistry, 382, (2001), 727-733.
Beck, H., et al., “Cathepsin S and an Asparagine-Specific Endoprotease Dominate the Proteolytic Processing of Human Myelin Basis Protein in vitro”,European Journal of Immunology, 31, (2001), 3726-3736.
Bird, R. E., “Single-Chain Antigen-Binding Proteins”,Science, 242(4877), (Oct. 21, 1988), 423-426.
Bretscher, M. S., et al., “Membrane Traffic During Cell Locomotion”,Current Opinion in Cell Biology, 10, (1998), 537-541.
Castino, R., et al., “Lysosomal Proteases as Potential Targets for the Induction of Apoptotic Cell Death in Human Neuroblastomas”,International Journal of Cancer, 97, (2002), 775-779.
Chakravarty, P. K., et al., “Plasmin-Activated Prodrugs for Cancer Chemotherapy, 2. Synthesis and Biological Activity of Peptidyl Derivatives of Doxorubicin”,Journal of Medicinal Chemistry, 26, (1983), 638-644.
Chambers, A. F., et al., “Changing Views of the Role of Matrix Metalloproteinases in Metastasis”,Journal of the National Cancer Institute, 89(17), (1977), 1260-1270.
Chang, C., et al., “The Many Faces of Metalloproteases: Cell Growth, Invasion, Angiogenesis and Metastasis”,Trends in Cell Biology, 11(11), (2001),S37-S43.
Chen, J.-M., et al., “Activation of Progelatinase A by Mammalian Legumain, a Recently Discovered Cysteine Proteinase”,Biological Chemistry, 382, (2001), 777-783.
Chen, J.-M., et al., “Cloning and Expression of Mouse Legumain, a Lysosomal Endopeptidase”,The Biochemical Journal, 335 (Part 1), (1998), 111-117.
Chen, J.-M. , et al., “Cloning, Isolation, and Characterization of Mammalian Legumain, an Asparaginyl Endopeptidase”,The Journal of Biological Chemistry, 272(12), (1997),8090-8098.
Choi, S. J., et al., “Identification of Human Asparaginyl Endopeptidase (Legumain) as an Inhibitor of Osteoclast Formation and Bone Resorption”,The Journal of Biological Chemistry, 274, (1999) , 27747-27753.
Choi, S. J., et al., “Osteoclast Inhibitory Peptide 2 Inhibits Osteoclast Formation via Its C-Terminal Fragment”,Journal of Bone and Mineral Research, 16(10), (2001), 1840-1811.
Chothia, C., “Domain Association in Immunoglobulin Molecules. The Packing of Variable Domains”,Journal of Molecular Biology. 186(3), (1985) , 651-663.
Clackson, T., “Making Antibody Fragments Using Phage Display Libraries”,Nature, 352(6336), (Aug. 15, 1991), 624-628.
Coulibaly, S., et al., “Modulation of Invasive Properties of Murine Squamous Carcinoma Cells by Heterologous Expression of Cathepsin B and Cystatin C”,International Journal of Cancer, 83, (1999), 526-531.
De Groot, F. M., et al., “Synthesis and Biological Evaluation of Novel Prodrugs of Anthracyclines for Selective Activation by the Tumor-Associated Protease Plasmin”,Journal of Medicinal Chemistry, 42(25), (1999), 5277-5283.
De Jong, J., et al., “Analysis and Pharmacokinetics ofN-I-leucyldoxorubicin and Metabolites in Tissues of Tumor-Bearing BALB/c Mice”,Cancer Chemotherapy and Pharmacology, 31, (1992), 156-160.
Denmeade, S. R., et al., “Enzymatic Activation of a Doxorubicin-Peptide Prodrug by Prostate-Specific Antigen”,Cancer Research, 58(12), (1998), 2537-2540.
Dubowchik, G. M., et al., “Cathepsin B-Sensitive Dipeptide Prodrugs. 2. Models of Anticancer Drugs Paclitaxel (Taxol®), Mitomycin C and Doxorubicin”,Bioorganic&Medicinal Chemistry Letters, 8, (1998), 3347-3352.
Dubowchik, G. M., et al., “Cathepsin B-Sensitive Dipeptide Prodrugs. 1. A Model Study of Structural Requirements for Efficient Release of Doxorubicin”,Bioorganic&Medicinal Chemistry Letters 8, (1998), 3341-3346.
Elbashir, S. M., et al., “Analysis of Gene Function in Somatic Mammalian Cells Using Small Interfering RNAs”,Methods, 26(2), (2002), 199-213.
Foghsgaard, L., et al., “Cathepsin B Acts as a Dominant Execution Protease in Tumor Cell Apoptosis Induced by Tumor Necrosis Factor”,The Journal of Cell Biology, 153(5), (2001), 999-1009.
Gravesen, A., et al., “Restriction Fragment Differential Display of Pediocin- ResistantListeria monocytogenes412 Mutants Shows Consistent Overexpression of a Putative β-Glucoside-Specific PTS System”,Microbiology, 146 (Part6), (2000), 1381-1389.
Hanahan, D., “The Hallmarks of Cancer”,Cell, 100, (2000), 57-70.
Hann, M. M., et al., “On the Double Bond Isostere of the Peptide Bond: Preparation of an Enkephalin Analgoue”,Journal of Chemical Society—Perkin Transactions1, No. 1, (1982), 307-314.
Hashimoto, S.-I., et al., “Serial Analysis of Gene Expression in Human Monocytes and Macrophages”,Blood, 94(3), (1999), 837-844.
Holladay, M. W., et al., “Synthesis of Hydroxyethylene and Ketomethylene Dipeptide Isosteres”,Tetrahedron Letters, 24 (41), (1983), 4401-4404.
Holliger, P., ““Diabodies”: Small Bivalent and Bispecific Antibody Fragments”,Proc. Natl. Acad. Sci. USA, 90(14), (Jul. 15, 199
Edgington Thomas S.
Liu Cheng
Cordero Garcia Marcela M
Schwegman Lundberg & Woessner, P.A.
The Scripps Research Institute
Tsang Cecilia
LandOfFree
Targeted delivery to legumain-expressing cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Targeted delivery to legumain-expressing cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeted delivery to legumain-expressing cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4113786